Preview

Нефрология

Расширенный поиск

АНТИ-C1q АУТОАНТИТЕЛА: НОВЫЕ ТЕСТЫ И КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ

Полный текст:

Аннотация

Хотя анти-dq аутоантитела были описаны более четырех десятилетий назад, постоянный поток статей, описывающих клинические ассоциации или функциональные последствия подтверждает, что анти-dq антитела по-прежнему актуальны. Безусловное большинство исследований сосредоточились на анти-C1q антителах при системной красной волчанке (СКВ). При СКВ анти-C1q антитела ассоциированы с наличием волчаночного нефрита и при их отсутствии развитие обострения нефрита маловероятно. Анти-C1q антитела встречаются не только при ряде аутоиммунных состояний, но также и у здоровых лиц. Несмотря на значительный прогресс, который был достигнут в понимании того, как анти-C1q антитела могут участвовать в повреждении тканей, до сих пор еще многое предстоит узнать о процессах, приводящих к нарушению толерантности к этому белку. Значительно усовершенствованы тесты, используемые для выявления анти-C1q антител. Надо надеяться, что эти новые стандартизированные тесты будут в ближайшее время использоваться при проведении крупных исследований клинических ассоциаций с независимой оценкой результатов. Подобные крупномасштабные исследования выявят истинное значение тестов на анти-C1q аутоантитела при ряде клинических состояний.

Об авторах

М. . Малер
INOVA Diagnostics, Inc
Россия


Р. А. Ван Шаренбург
Лейденский университет
Россия


Л. А. Трау
Лейденский университет
Россия


Список литературы

1. Trouw L.A., Roos A., Daha M.R. Autoantibodies to complement components. Mol Immunol 2001; 38, 199-206

2. Norsworthy P. Davies K.A. Complement components and their autoantibodies. Mol Biotechnol 2003; 23, 259-270

3. Daha N.A., Banda N.K., Roos A., et al. Complement activation by (auto) antibodies. Mol Immunol 2011; 48, 1656-1665

4. Cooper N.R. The classical complement pathway: activation and regulation of the first complement component. Adv Immunol 1985; 37, 151-216

5. Feinstein A., Munn E.A., Richardson N.E. The three-dimensional conformation of M and A globulin molecules. Ann N Y Acad Sci 1971; 190, 104-121

6. Agnello V., Koffler D., Eisenberg J.W., et al. C1g precipitins in the sera of patients with systemic lupus erythematosus and other hypocomplementemic states: characterization of high and low molecular weight types. J Exp Med 1971; 134, 228s-241s

7. Wener M.H., Mannik M., Schwartz M.M., Lewis E.J. Relationship between renal pathology and the size of circulating immune complexes in patients with systemic lupus erythematosus. Medicine(Baltimore)1987; 66, 85-97

8. Uwatoko S., Aotsuka S., Okawa M., et al. Characterization of C1q-binding IgG complexes in systemic lupus erythematosus. Clin ImmunolImmunopathol 1984; 30, 104-116

9. Uwatoko S., Aotsuka S., Okawa M., et al. C1q solid-phase radioimmunoassay: evidence for detection of antibody directed against the collagen-like region of C1q in sera from patients with systemic lupus erythematosus. Clin Exp Immunol 1987; 69, 98-106

10. Antes U., Heinz H.P., Loos M. Evidence for the presence of autoantibodies to the collagen-like portion of C1q in systemic lupus erythematosus. Arthritis Rheum 1988; 31, 457-464

11. Kohro-Kawata J., Wener M.H., Mannik M. The effect of high salt concentration on detection of serum immune complexes and autoantibodies to C1q in patients with systemic lupus erythematosus. J Rheumatol 2002; 29, 84-89

12. Golan M.D., Burger R., Loos M. Conformational changes in C1q after binding to immune complexes: detection of neoantigens with monoclonal antibodies. J Immunol 1982; 129, 445-447

13. Schaller M., Bigler C., Danner D., et al. Autoantibodies against C1q in systemic lupus erythematosus are antigen-driven. J Immunol 2009; 183, 8225-8231

14. Wener M.H., Uwatoko S., Mannik M. Antibodies to the collagen-like region of C1q in sera of patients with autoimmune rheumatic diseases. Arthritis Rheum 1989; 32, 544-551

15. Vanhecke D., Roumenina L.T., Wan H., et al. Identification of a major linear C1q epitope allows detection of systemic lupus erythematosus anti-C1q antibodies by a specific peptide-based enzyme-linked immunosorbent assay. Arthritis Rheum 2012; 64, 3706-3714

16. Tsacheva I., Radanova M., Todorova N., et al. Detection of autoantibodies against the globular domain of human C1q in the sera of systemic lupus erythematosus patients. Mol Immunol 2007; 44, 2147-2151

17. Hogarth M.B., Norsworthy P.J., Allen P.J., et al. Autoantibodies to the collagenous region of C1q occur in three strains of lupusprone mice. Clin Exp Immunol 1996; 104, 241-24

18. Trouw L.A., Seelen M.A., Duijs J.M., et al. Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies. Clin Exp Immunol 2003; 132, 32-39

19. Trouw L.A., Groeneveld T.W., Seelen M.A., et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 2004; 114, 679-688

20. Trouw L.A., Seelen M.A., Visseren R., et al. Anti-C1q autoantibodies in murine lupus nephritis. Clin Exp Immunol 2004; 135, 41-48

21. Trendelenburg M., Lopez-Trascasa M., Potlukova E., et al. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant 2006; 21, 3115-3121

22. Potlukova E., Kralikova P. Complement component c1q and anti-c1q antibodies in theory and in clinical practice. Scand J Immunol 2008; 67, 423-430

23. Heidenreich U., Mayer G., Herold M., et al. Sensitivity and specificity of autoantibody tests in the differential diagnosis of lupus nephritis. Lupus 2009; 18, 1276-1280

24. Meyer O.C., Nicaise-Roland P., Cadoudal N., et al. Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus. Arthritis Res Ther 2009; 11, R87

25. Cai X., Yang X., Lian F., et al. Correlation between serum anti-C1q antibody levels and renal pathological characteristics and prognostic significance of anti-C1q antibody in lupus nephritis. J Rheumatol 2010; 37, 759-765

26. Akhter E., Burlingame R.W., Seaman A.L., et al. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus 2011; 20, 1267-1274

27. Julkunen H., Ekblom-Kullberg S., Miettinen A. Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4. RheumatolInt 2012; 32, 2445-2451

28. Trendelenburg M. Antibodies against C1q in patients with systemic lupus erythematosus. Springer Semin Immunopathol 2005; 27, 276-285

29. Siegert C.E., Daha M.R., Halma C., et al. IgG and IgA autoantibodies to C1q in systemic and renal diseases. Clin Exp Rheumatol 1992; 10, 19-23

30. Trendelenburg M., Marfurt J., Gerber I., et al. Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis Rheum 1999; 42, 187-188

31. Horvath L., Czirjak L., Fekete B., et al. Levels of antibodies against C1q and 60 kDa family of heat shock proteins in the sera of patients with various autoimmune diseases. Immunol Lett 2001; 75, 103-109

32. Potlukova E., Jiskra J., Limanova Z., et al. Autoantibodies against complement C1q correlate with the thyroid function in patients with autoimmune thyroid disease. Clin Exp Immunol 2008; 153, 96-101

33. Siegert C.E., Daha M.R., Swaak A.J., et al. The relationship between serum titers of autoantibodies to C1q and age in the general population and in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1993; 67, 204-209

34. Wisnieski J.J., Jones S.M. Comparison of autoantibodies to the collagen-like region of C1q in hypocomplementemic urticarial vasculitis syndrome and systemic lupus erythematosus. J Immunol 1992; 148, 1396-1403

35. Sinico R.A., Rimoldi L., Radice A., et al. Anti-C1q autoantibodies in lupus nephritis. Ann N Y Acad Sci 2009; 1173, 47-51

36. Hunnangkul S., Nitsch D., Rhodes B., et al. Familial clustering of non-nuclear autoantibodies and C3 and C4 complement components in systemic lupus erythematosus. Arthritis Rheum 2008; 58, 1116-1124

37. Prohaszka Z., Daha M.R., Susal C., et al. C1q autoantibodies in HIV infection: correlation to elevated levels of autoantibodies against 60-kDa heat-shock proteins. Clin Immunol 1999; 90, 247-255

38. Saadoun D., Sadallah S., Trendelenburg M., et al. Anti-C1q antibodies in hepatitis C virus infection. Clin Exp Immunol 2006; 145, 308-312

39. Seelen M.A., Trouw L.A., Daha M.R. Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Curr Opin Nephrol Hypertens 2003; 12, 619-624

40. Mok C.C., Ho L.Y., Leung H.W., Wong L.G. Performance of anti-C1q, antinucleosome, and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus. Transl Res 2010; 156, 320-325

41. Matrat A., Veysseyre-Balter C., Trolliet P., et al. Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares. Lupus 2011; 20, 28-34

42. Yang X.W., Tan Y., Yu F., Zhao M.H. Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis. Nephrol Dial Transplant 2012; 27, 3552-3559

43. Moura C.G., Mangueira C.L., Cruz L.A., Cruz C.M. Negative anti-C1q antibody titers may influence therapeutic decisions and reduce the number of renal biopsies in systemic lupus erythematosus. Nephron Clin Pract 2011; 118, c355-c360

44. Zhang C.Q., Ren L., Gao F. et al. Anti-C1q antibodies are associated with systemic lupus erythematosus disease activity and lupus nephritis in northeast of China. Clin Rheumatol 2011; 30, 967-973

45. Pradhan V., Rajadhyaksha A., Mahant G., et al. Anti-C1q antibodies and their association with complement components in Indian systemic lupus erythematosus patients. Indian J Nephrol 2012; 22, 353-357

46. ElGendi S.S., El-Sherif WT Anti-C1q antibodies, sCD40L, TWEAK and CD4/CD8 ratio in systemic lupus erythematosus and their relations to disease activity and renal involvement. Egypt J Immunol 2009; 16, 135-148

47. Moroni G., Trendelenburg M., Del P.N., et al. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 2001; 37, 490-498

48. Yin Y., Wu X., Shan G., Zhang X. Diagnostic value of serum anti-C1q antibodies in patients with lupus nephritis: a metaanalysis. Lupus 2012; 21, 1088-1097

49. Horvath L., Czirjak L., Fekete B., et al. High levels of antibodies against Clq are associated with disease activity and nephritis but not with other organ manifestations in SLE patients. Clin Exp Rheumatol 2001b; 19, 667-672

50. Grootscholten C., Dieker J.W., McGrath F.D., et al. A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone. Ann Rheum Dis 2007; 66, 693-696

51. Hiepe F., Pfuller B., Wolbart K., et al. C1q: a multifunctional ligand for a new immunoadsorption treatment. Ther Apher 1999; 3, 246-251

52. Berner B., Scheel A.K., Schettler V., et al. Rapid improvement of SLE-specific cutaneous lesions by C1q immunoadsorption. Ann Rheum Dis 2001; 60, 898-899

53. Pfueller B., Wolbart K., Bruns A., et al. Successful treatment of patients with systemic lupus erythematosus by immunoadsorption with a C1q column: a pilot study. Arthritis Rheum 2001; 44, 1962-1963

54. Papp K., Vegh P., Hobor R., et al. Immune complex signatures of patients with active and inactive SLE revealed by multiplex protein binding analysis on antigen microarrays. PLoS ONE 2012; 7: e44824

55. Kalunian K.C., Chatham W.W., Massarotti E.M., et al. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis Rheum 2012; 64, 4040-4047

56. Stohl W., Hilbert D.M. The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol 2012; 30, 69-77

57. Kalunian K., Joan T.M. New directions in the treatment of systemic lupus erythematosus. Curr. Med Res Opin 2009; 25, 1501-1514

58. Stinton L.M., Barr S.G., Tibbles L.A., et al. Autoantibodies in lupus nephritis patients requiring renal transplantation. Lupus 2007; 16, 394-400

59. Uwatoko S., Gauthier V.J., Mannik M. Autoantibodies to the collagen-like region of C1Q deposit in glomeruli via C1Q in immune deposits. Clin Immunol Immunopathol 1991; 61, 268-273

60. Mannik M., Wener M.H. Deposition of antibodies to the collagen-like region of C1q in renal glomeruli of patients with proliferative lupus glomerulonephritis. Arthritis Rheum 1997; 40, 1504-1511

61. Siegert C.E., Daha M.R., Lobatto S., et al. IgG autoantibodies to C1q do not detectably influence complement activation in vivo and in vitro in systemic lupus erythematosus. Immunol Res 1992, 11, 91-97

62. Bigler C., Hopfer H., Danner D., Schaller et al. Anti-C1q autoantibodies do not correlate with the occurrence or severity of experimental lupus nephritis. Nephro. Dial Transplant 2011; 26, 1220-1228

63. Kozyro I., Korosteleva L., Chernoshej D., et al. Autoantibodies against complement C1q in acute post-streptococcal glomerulonephritis. Clin Immunol 2008; 128, 409-414

64. Bigler C., Schaller M., Perahud I., et al. Autoantibodies against complement C1q specifically target C1q bound on early apoptotic cells. J Immunol 2009; 183, 3512-3521

65. Trouw L.A., Bengtsson A.A., Gelderman K.A., et al. C4b-binding protein and factor H compensate for the loss of membrane bound complement inhibitors to protect apoptotic cells against excessive complement attack. J Biol Chem 2007; 282, 28540-28548

66. Trouw L.A., Blom A.M., Gasque P. Role of complement and complement regulators in the removal of apoptotic cells. Mol Immunol 2008; 45, 1199-1207


Для цитирования:


Малер М..., Ван Шаренбург Р.А., Трау Л.А. АНТИ-C1q АУТОАНТИТЕЛА: НОВЫЕ ТЕСТЫ И КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ. Нефрология. 2014;18(1):8-13.

For citation:


Mahler M..., Van Schaarenburg R.A., Trouw L.A. Anti-C1q autoantibodies, novel tests, and clinical consequences. Nephrology (Saint-Petersburg). 2014;18(1):8-13. (In Russ.) (In Russ.)

Просмотров: 145


ISSN 1561-6274 (Print)
ISSN 2541-9439 (Online)